Does fluoxetine reverse the effects of early life stress on the CNS corticotropin-releasing factor system and improve psychological and neuroendocrine function?: a therapy outcome study in women with childhood abuse experiences

Trial Profile

Does fluoxetine reverse the effects of early life stress on the CNS corticotropin-releasing factor system and improve psychological and neuroendocrine function?: a therapy outcome study in women with childhood abuse experiences

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2009 Actual end date (November 2007) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top